WuXi AppTec’s Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80% to meet global preclinical testing needs and to enable the acceleration of development timelines. With the expansion, the toxicology facility will cover an area of 580,000 square feet and execute full-service preclinical and clinical stage safety assessments for biologic and small molecule drugs.

“By investing in the toxicology facility, we are answering the call for increased safety assessment capacity for global customers,” said Dr. Steve Yang, executive vice president, chief business officer of WuXi AppTec. “WuXi AppTec LTD is committed to enabling our customers to advance the drug development process and bring new treatment to patients in need.”

The toxicology unit of WuXi AppTec LTD provides discovery, IND- and NDA-enabling studies for global customers. The unit has full AAALAC accreditation and has successfully passed inspections by the FDA, OECD, NMPA. LTD provides services from Shanghai, Nanjing, Suzhou facilities in China, as well as St. Paul, Atlanta, Plainsboro and Cranbury facilities in USA.